US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexaria Bioscience Corp

0.2010

-0.0341-14.50%

Volume:705.00

Turnover:146.07

Market Cap:1.03M

PE:- -

High:0.2370

Open:0.2022

Low:0.2010

Close:0.2351

Loading ...

Overview Company News Filings

Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study

Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Lexaria Updates Current GLP-1 Market

Lexaria Appoints Michael Shankman as Chief Financial Officer

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3

LEXX: Changing Gears: Christopher Takes Over as CEO

Zacks Small Cap Research

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LEXXW/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LEXXW"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LEXXW\",,,,,undefined,":{"symbol":"LEXXW","market":"US","secType":"STK","nameCN":"Lexaria Bioscience Corp","latestPrice":0.201,"timestamp":1741896000000,"preClose":0.2351,"halted":0,"volume":705,"delay":0,"changeRate":-0.145045,"change":-0.0341,"floatShares":5104300,"shares":5104300,"lyrEps":0,"pbRate":0.1,"amount":146.066,"amplitude":0.153126,"volumeRatio":0.24468972281090057,"dividePrice":0,"prevYearClose":0.7641,"fiveDayClose":0.2399,"twentyDayClose":0.24},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LEXXW\",,,,,undefined,":{"symbol":"LEXXW","floatShares":5104300,"roa":"-67.50%","roe":"-114.83%","lyrEps":0,"volumeRatio":0.24468972281090057,"shares":5104300,"dividePrice":0,"high":0.237,"amplitude":0.153126,"preClose":0.2351,"low":0.201,"week52Low":0.16,"pbRate":"0.10","psRate":"2.06","week52High":2.07,"institutionHeld":0,"latestPrice":0.201,"eps":0,"divideRate":0,"volume":705,"delay":0,"ttmEps":0,"open":0.202202,"prevYearClose":0.7641,"prevWeekClose":0.23,"prevMonthClose":0.249,"prevQuarterClose":0.7641,"fiveDayClose":0.2399,"twentyDayClose":0.24,"sixtyDayClose":0.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LEXXW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LEXXW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LEXXW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LEXXW\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2486392993","title":"Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2486392993","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486392993?lang=en_us&edition=fundamental","pubTime":"2024-11-28 19:01","pubTimestamp":1732791667,"startTime":"0","endTime":"0","summary":"NasdaqCM:LEXX Earnings and Revenue History November 28th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 15%. Earnings per share  missed analyst estimates by 6.8%.Looking ahead, revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.The company's shares are down 5.0% from a week ago.We don't want to rain on the parade too much, but we did also find 6 warning signs for Lexaria Bioscience (2 shouldn't be ignored!) that you need to be mindful of.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-bioscience-full-2024-earnings-110107270.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXX","LEXXW"],"gpt_icon":1},{"id":"2486015360","title":"Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2486015360","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486015360?lang=en_us&edition=fundamental","pubTime":"2024-11-26 22:20","pubTimestamp":1732630800,"startTime":"0","endTime":"0","summary":"Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and more. GLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come. KELOWNA, BC / ACCESSWIRE / November 26, 2024 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, provides the following strategic update.Today's GLP-1 drug market consists primarily of semaglutide , owned by Novo Nordisk; and tirzepatide , owned by Eli Lilly. All five of those drug brands, with the exception of Rybelsus, are administered by injection, whereas Rybelsus is the only oral tablet currently approved by the FDA today. While these two drugs were originally approved by the FDA for diabetes management, weight-loss approvals soon followed and Wegovy was also approved by the FDA in March 2024 to reduce the risk of cardiovascular death, heart attack and stroke.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revolutionizing-healthcare-lexaria-highlights-expanding-142000530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","BK4144","BK4007","LEXX","GLP","HCSG","LEXXW","BK4590"],"gpt_icon":0},{"id":"2486087496","title":"Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled","url":"https://stock-news.laohu8.com/highlight/detail?id=2486087496","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486087496?lang=en_us&edition=fundamental","pubTime":"2024-11-25 22:00","pubTimestamp":1732543200,"startTime":"0","endTime":"0","summary":"DehydraTECH-processed tirzepatide from Zepbound is being tested in an oral dose format. KELOWNA, BC / ACCESSWIRE / November 25, 2024 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms is pleased to announce that dosing has been completed for human pilot study #3  investigating a DehydraTECH-processed version of the dual action glucagon-like peptide-1  + glucose-dependent insulinotropic peptide  receptor agonist tirzepatide  in an oral dose format.The Study has been dosed in nine  healthy volunteers. The final seven-day dosing phase, wherein all subjects received the opposite treatment condition from that which they received during the initial dosing phase, was completed on November 16th. The initial dosing phase of either a seven-day regimen of oral DehydraTECH-processed tirzepatide capsules or a single injected tirzepatide dose was reported upon positively several weeks ago.No serious adverse events have been observed thus far during both dosing visits, which ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexarias-glp-1-human-pilot-140000385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXX","BK4144","GLP","BK4007","LEXXW","BK4590"],"gpt_icon":0},{"id":"2484112107","title":"ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2484112107","media":"ACCESSWIRE","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484112107?lang=en_us&edition=fundamental","pubTime":"2024-11-20 22:05","pubTimestamp":1732111500,"startTime":"0","endTime":"0","summary":"DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus control group in both body weight-loss, by 11.53% and 10.65% respectively, and in blood sugar, by 11.13% and 3.35% respectively.DehydraTECH-semaglutide compositions with and without SNAC technology outperformed Rybelsus control in body weight. Weight-control improvement demonstrated in ALL study groups during the final 4-weeks. Outcomes are strongly supportive of pending Phase 1b Australian human study. The Study results were highlighted by the fact that all groups utilizing Lexaria's proprietary DehydraTECH technology outperformed Rybelsus in body weight-control, as well as experienced body weight-control improvement during the final 4-weeks of the Study.Study group \"L\" was a positive control wherein the animals received unadulterated Rybelsus as the only FDA-approved oral GLP-1 drug on the market today, to utilize as a so-called \"standard of care\" . ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/study-groups-using-dehydratech-processing-140500657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALL","LEXX","GLP","LEXXW","R"],"gpt_icon":0},{"id":"2483809054","title":"Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2483809054","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483809054?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:10","pubTimestamp":1731593400,"startTime":"0","endTime":"0","summary":"World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules. KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / November 14, 2024 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, announces it has engaged a contract research organization to perform the world's first-ever fluorescently tagged DehydraTECH-semaglutide  rodent biodistribution study .Distribution of a drug once it enters the body can provide vital clues as to the understanding of that drug's ability to bind with targeted receptor cells, avoid concentration at physical sites that might be prone to fostering adverse side effects, and increase the drug's ultimate efficacy. Lexaria hopes to discover whether the DehydraTECH processing of semaglutide improves its biodistribution in any significant way compared to conventional orally administered semaglutide formulation practices.DehydraTECH is Lexaria's patented drug delivery formulation and processing platform technology which improves the w","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-signs-contract-dehydratech-glp-141000351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLP","LEXXW","BK4007","LEXX","BK4590","BK4144"],"gpt_icon":0},{"id":"2483881047","title":"Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2483881047","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483881047?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:20","pubTimestamp":1731507600,"startTime":"0","endTime":"0","summary":"DehydraTECH clinical test article manufacturing has been completed. KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee  approval that was required before dosing can begin in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, .The Company is also announcing that clinical test article manufacturing for all planned Study arms has already been completed. This includes production for the four planned DehydraTECH formulation Study arms and clinical repackaging of the commercially available Rybelsus comparator tablets for the Study control arm as follows:. Arms 2 and 3 of the Study will use DehydraTECH-processed pure semaglutide and will be compared to Study Arm 4 which will use Rybelsus tablets  that contains Novo Nordis","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ethics-board-approval-granted-lexarias-142000879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BMPRXR70.SGD","LEXXW","BK4585","ACB","BK4141","BK4144","IE00BMPRXN33.USD","IE00BMPRXQ63.HKD","LU0348723411.USD","BK4557","GLP","BK4007","BK4588","LEXX","BK4590"],"gpt_icon":1},{"id":"2481185121","title":"Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2481185121","media":"ACCESSWIRE","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481185121?lang=en_us&edition=fundamental","pubTime":"2024-11-07 22:15","pubTimestamp":1730988900,"startTime":"0","endTime":"0","summary":"DehydraTECH for GLP-1 being optimized for global pharmaceutical use. Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH drug delivery platform for application in the GLP-1 space, positioning it as a \"must-have\" technology for larger companies seeking to develop, defend or increase their cash flows from existing drugs as well as to be utilized in early stages of drug development for next-gen GLP-1 drugs due to hit the market in 2026, 2027, and beyond.Developing or acquiring their own new GLP-1 and related molecules under traditional drug development techniques;Developing or acquiring technologies and intellectual property  that improves the delivery pharmacokinetics of GLP-1 in attempts to increase drug absorption and decrease drug side effects; and,Developing or acquiring related technologies and IP that can act as platforms for improved drug performance and patient outcomes.On November 4, 2024, Ascendis Pharma announced it had granted an exclusive","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-updates-fast-moving-glp-141500201.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4585","FAST","BK4141","GLP","IE00BMPRXQ63.HKD","LU0348723411.USD","NVO","BK4104","LEXXW","BK4590","BK4144","BK4567","IE00BMPRXN33.USD","IE00BMPRXR70.SGD","VKTX","LEXX","LLY","BK4588"],"gpt_icon":1},{"id":"2477636032","title":"Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2477636032","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477636032?lang=en_us&edition=fundamental","pubTime":"2024-10-24 21:10","pubTimestamp":1729775400,"startTime":"0","endTime":"0","summary":"DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups. KELOWNA, BC / ACCESSWIRE / October 24, 2024 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms announces that it has received partial 12-week  blood sugar results from the recently completed animal study WEIGHT-A24-1 .- Recalculations led to slight changes from earlier reported data. Lexaria is strongly encouraged that the DehydraTECH-liraglutide and DehydraTECH-CBD groups A and B outperformed all three of the Rybelsus and pure semaglutide DehydraTECH composition groups regardless of whether the semaglutide had or had not been processed with the salcaprozate sodium technology known as \"SNAC\". Rybelsus, which utilizes Novo Nordisk's proprietary SNAC technology, is the world's only orally administered GLP-1 drug brand.Usually, injected versions of drugs have greater efficacy than orally administered versions of the same drug because of superior pharmacokine","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-partial-12-week-blood-131000880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4557","GLP","BK4590","LEXX","BK4007","LEXXW","ACB","BK4144"],"gpt_icon":0},{"id":"2477192332","title":"Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2477192332","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477192332?lang=en_us&edition=fundamental","pubTime":"2024-10-22 21:20","pubTimestamp":1729603200,"startTime":"0","endTime":"0","summary":"DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groups. Accelerated rates of weight loss were experienced during the final 4 weeks of the study in all DehydraTECH groups. KELOWNA, BC / ACCESSWIRE / October 22, 2024 / Lexaria Bioscience Corp.  &  , a global innovator in drug delivery platforms announces that it has received partial 12-week  body weight results from the recently completed animal study WEIGHT-A24-1 .Recalculations led to slight changes from earlier reported data. This Study is the world's first to evaluate the relative performance of liraglutide processed with DehydraTECH. In humans, semaglutide has been shown in other studies to be more than twice as effective at promoting weight loss as liraglutide . Thus, the outperformance of DehydraTECH-liraglutide compared to DehydraTECH-semaglutide is of notable interest. In this Study, the processed liraglutide in Study group H was administered orally even though it is injected w","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-partial-12-week-body-132000487.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4559","GLP","TEVA","BK4590","BK4588","BK4566","BK4584","BK4557","LEXX","BK4144","BK4007","BK4585","LEXXW"],"gpt_icon":0},{"id":"2475050608","title":"Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2475050608","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475050608?lang=en_us&edition=fundamental","pubTime":"2024-10-15 20:25","pubTimestamp":1728995100,"startTime":"0","endTime":"0","summary":"KELOWNA, BC / ACCESSWIRE / October 15, 2024 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 4,551,019 shares of common stock at an exercise price of $3.06 per share. The warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants  and will expire five years from the Stockholder Approval Date. The closing of the offering is expected to occur on or about October 16, 2024, subject to the satisfaction of customary closing conditions.H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-announces-5-million-registered-122500988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","IE00B3QW5Z07.USD","NDAQ","IE00B64PRP62.GBP","LEXX","LU2095319765.USD","LU2210150020.SGD","BK4112",".IXIC","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210149790.SGD","BK4007","BK4585","LEXXW"],"gpt_icon":0},{"id":"2474228602","title":"Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2474228602","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474228602?lang=en_us&edition=fundamental","pubTime":"2024-10-09 21:05","pubTimestamp":1728479100,"startTime":"0","endTime":"0","summary":"DehydraTECH-processed tirzepatide from Zepbound is being tested in an oral dose format. The Study is being conducted in up to 10 healthy volunteers. The initial seven day dosing phase of either an oral DehydraTECH-processed tirzepatide capsule or a single injected tirzepatide dose is scheduled to be completed on October 13th. After a multi-week washout period, the second  seven day dosing phase will be administered in mid-November where subjects will receive the alternate treatment condition than what was received during the initial dosing phase. No serious adverse events have been observed thus far during this initial dosing phase.About the StudyMany design characteristics of the Study, also referred to as Study GLP-1-H24-3, are similar to Lexaria's initial GLP-1 human pilot study #1. The DehydraTECH-tirzepatide test articles were compound formulated using Zepbound, strictly for research purposes, dosed to the subjects under fasted conditions. The Study is designed to measure tolerabi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexarias-glp-1-human-pilot-130500048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","GLP","LEXX","BK4144","BK4590","LEXXW"],"gpt_icon":0},{"id":"2473420841","title":"Lexaria Updates Current GLP-1 Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2473420841","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473420841?lang=en_us&edition=fundamental","pubTime":"2024-10-08 21:20","pubTimestamp":1728393600,"startTime":"0","endTime":"0","summary":"KELOWNA, BC / ACCESSWIRE / October 8, 2024 / Lexaria Bioscience Corp.  &  , a global innovator in drug delivery technology, provides an update on recent glucagon-like peptide-1  receptor agonist market sector advancements.In 2020 the total market size for GLP-1 drugs was less than $4 billion . That same year, Novo Nordisk paid $1.8 billion to purchase Emisphere's SNAC drug delivery technology which was subsequently incorporated into Rybelsus semaglutide oral tablets, resulting in the first and only Food and Drug Administration  approved GLP-1 drug for use as an oral tablet.Analysts around the world have been trying to keep up with GLP-1 trends. Compounding the difficulty in doing so is projecting which major pharmaceutical firms will achieve approval for GLP-1/GIP and related drugs currently in the development pipeline. Tirzepatide, for example, was only approved by the FDA in May, 2022, but Eli Lilly is forecasting $15 billion in revenue from the drug during calendar 2024.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-updates-current-glp-1-132000450.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4144","BK4007","LEXX","GLP","LEXXW","BK4590"],"gpt_icon":0},{"id":"2472375708","title":"Lexaria Appoints Michael Shankman as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2472375708","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472375708?lang=en_us&edition=fundamental","pubTime":"2024-10-01 21:25","pubTimestamp":1727789100,"startTime":"0","endTime":"0","summary":"KELOWNA, BC / ACCESSWIRE / October 1, 2024 / Lexaria Bioscience Corp.  &  , a global innovator in drug delivery platforms announces the appointment of Michael Shankman, CPA, as Chief Financial Officer  effective immediately. As a member of the executive leadership team, Mr. Shankman will lead the Company's financial operations.\"Mike is an accomplished individual who brings a wealth of financial and regulatory knowledge and experience to the table,\" said Richard Christopher, Chief Executive Officer of Lexaria. \"On behalf of the entire Lexaria team, I'm thrilled to welcome Mike as our CFO as we continue to strengthen our executive team in expectations of strong growth into 2025.\". CAUTION REGARDING FORWARD-LOOKING STATEMENTSThis press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as \"anticipate,\" \"if,\" \"believe,\" \"plan,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"could,\" \"sho","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-appoints-michael-shankman-chief-132500019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXX","CFO","LEXXW","BK4007"],"gpt_icon":0},{"id":"2470902085","title":"Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3","url":"https://stock-news.laohu8.com/highlight/detail?id=2470902085","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470902085?lang=en_us&edition=fundamental","pubTime":"2024-09-27 21:20","pubTimestamp":1727443200,"startTime":"0","endTime":"0","summary":"First-ever DehydraTECH-processed tirzepatide from Zepbound to be tested in a swallowed oral format. KELOWNA, BC / ACCESSWIRE / September 27, 2024 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms is pleased to announce that approval has been received from an independent review board, for human pilot study #3 , investigating a DehydraTECH-processed version of the dual action GLP-1  + GIP  tirzepatide in an oral dose format.Subject recruitment will begin shortly and the Company will announce as soon as the first dosing has begun, currently expected in late October. Lexaria anticipates the final doses in the study to be administered in late November.The Study will be conducted in up to 10 healthy volunteers and will study a single injected dose of Zepbound  monitored over a 7-day duration, compared to 7 consecutive days of daily oral dosing of DehydraTECH-processed Zepbound.Many design characteristics of the Study, also referred to as Study GLP-1-H24-3, are simil","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-receives-independent-review-board-132000601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXXW","LEXX","BK4007"],"gpt_icon":0},{"id":"2469110066","title":"LEXX: Changing Gears: Christopher Takes Over as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2469110066","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469110066?lang=en_us&edition=fundamental","pubTime":"2024-09-23 18:07","pubTimestamp":1727086020,"startTime":"0","endTime":"0","summary":"Chris Bunka Passes CEO Role to Richard Christopher. As part of the transition, Lexaria has developed a 100-day plan which builds on the recent announcement of a Material Transfer Agreement  with a pharmaceutical company. The elements of the plan include:. On September 3rd, Lexaria announced its entry into a Material Transfer Agreement  with an undisclosed pharmaceutical company. Details about the arrangement were sparse on account of the partner desiring to remain anonymous until the safety and pharmacokinetic  profiles are confirmed. The goal of the arrangement is to use DehydraTECH to improve the side effect profile and PK for a product that is already on the market. Lexaria will provide the partner a temporary exclusive license to evaluate certain DehydraTECH concepts and formulations. The MTA-related work should be complete within six months. If it is successful, the arrangement","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexx-changing-gears-christopher-takes-100700784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXXW","BK4007","BK4188","LEXX","MTA","PK","BK4218","BK4181"],"gpt_icon":0}],"pageSize":16,"totalPage":2,"pageCount":2,"totalSize":31}]}}